HTFL Soars After Q2 Beat And Raised 2026 Revenue Outlook
HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.
How this was made

The 30-second read
Why it matters
Earnings beat and guidance raise expectations for revenue growth and margin improvement.
Market read
First‑report earnings and guidance move the stock sharply, offering a clear trading catalyst.
What to watch
Potential regulatory or reimbursement hurdles for new imaging tech.
Background
Heartflow provides non‑invasive coronary artery disease assessment using CT imaging.
Ticker impact
Q2 earnings beat and raised 2026 revenue guidance caused a 9.6% price jump.
Potential upside to $55‑$60 in the near term.
Strong gross margin, cash position and guidance lift expectations despite losses.
Market effects
Highlights growth potential in cardiovascular imaging, may lift peers.
U.S. healthcare tech sector sees renewed interest.
Limited to U.S. listed health‑tech stocks.
Counterpoint
Losses remain deep; execution risk could stall momentum.
Key entities
- companyHeartflow, Inc.
Cardiovascular imaging technology provider.



